| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| Neprilysin | Human Neprilysin / MME / CD10 Protein, Tag Free (active enzyme) | Human | HEK293 | ![]() | SDS-PAGE | $410.00 50ug | ||
| Neprilysin | Human Neprilysin / MME / CD10 Protein, His Tag (active enzyme, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $368.00 100ug | ||
| Neprilysin | Human Neprilysin / MME / CD10 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $290.00 50ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Dexecadotril | Phase 3 Clinical | Bioprojet Pharma | Gastrointestinal Diseases | 상세 | |
| Sacubitril/Valsartan (Chong Kun Dang Pharmaceutical) | CKD-202A | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Essential Hypertension | 상세 |
| QR-12000 | QR-12000 | Phase 3 Clinical | Wuhan Createrna Science and Technology Co Ltd | Essential Hypertension; Hypertension | 상세 |
| Debio-0827 | PL-37; Debio-0827 | Phase 2 Clinical | Pharmaleads | Pain | 상세 |
| Sacubitril | AHU-377 | Phase 2 Clinical | Novartis Pharma Ag | Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Diabetes Mellitus; Essential Hypertension; Heart Failure; Hypertension; Insulin Resistance; Metabolic Diseases | 상세 |
| Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 상세 | |
| Sacubitril Valsartan Sodium Extended-Relesae Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Heart Failure | 상세 | |
| Sacubitril/Allisartan Isoproxil/Amlodipine Besylate | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Essential Hypertension | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacubitril/Allisartan Isoproxil | AHU-377/EXP3174; S-086 | Approved | Shenzhen Salubris Pharmaceuticals Co Ltd | 信超妥 | Mainland China | Essential Hypertension | Shenzhen Salubris Pharmaceuticals Co Ltd | 2025-05-20 | Essential Hypertension; Heart Failure; Hypertension | 상세 |
| Sacubitril/Valsartan Sodium Hydrate | LCZ-696; LCZ-696A | Approved | Novartis Pharma Ag | ENTRESTO SPRINKLE, Enresuto, Enrest, Entresto, Neparvis, 诺欣妥, 科畅欣 | United States | Heart Failure | Novartis Pharmaceuticals Corp | 2015-07-07 | Breast Neoplasms; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Erectile Dysfunction; Essential Hypertension; Heart Defects, Congenital; Heart Diseases; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Hepatic Insufficiency; Hypertension; Lymphoma; Myocardial Infarction; Obesity; Peripheral Arterial Disease; Postmyocardial Infarction Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left | 상세 |
| Racecadotril | Tiorfan; Hidrasec | Approved | Bioprojet Pharma | France | Diarrhea | Bioprojet Pharma | 1993-03-23 | Diarrhea; Diarrhea, Infantile; Sepsis | 상세 |